放疗在乳腺癌软脑膜病变中的作用:多中心分析
该多中心研究分析2005至2020年三家学术中心收治的232例女性乳腺癌软脑膜病变患者,中位总生存4.7个月,放疗未与总生存改善相关,全身治疗与总生存改善相关。
要点
- 乳腺癌软脑膜病变患者中位总生存仅4.7个月,预后差。
- 66.4%患者接受放疗,但放疗未与总生存改善相关。
- 全身治疗与总生存改善相关,尤其在KPS较差患者中。
核心结论
- 乳腺癌软脑膜病变预后差,中位总生存4.7个月。
- 放疗未与总生存改善相关,全身治疗与总生存改善相关。
研究设计与样本
- 多中心研究分析2005至2020年三家学术中心收治的232例女性乳腺癌软脑膜病变患者。
主要发现
- 软脑膜病变诊断时中位年龄54.5岁,中位KPS为80%。
- 53.8%患者病变局限于脑,66.4%接受放疗,61.6%接受全身治疗。
- 中位随访4.5个月(范围0.1-72.0个月),观察到220例死亡。
- 中位总生存4.7个月(95%CI:3.9-5.5)。
临床怎么用
- 放疗未显示总生存获益,需结合全身治疗状态评估放疗时机。
- 全身治疗与总生存改善相关,尤其KPS较差患者。
局限性
- 回顾性多中心设计,放疗与总生存的获益评估受治疗交互和时间影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A subset of breast cancer patients will eventually develop leptomeningeal disease (LMD). There is a lack of large, in-depth analyses of the pattern of care and outcomes, with a particular focus on radiation therapy (RT). We report our experience in interdisciplinary LMD management, specifically addressing the role of RT. MATERIALS AND METHODS: This multicenter study analyzed female breast cancer patients with LMD treated at three academic centers between 2005 and 2020. RESULTS: A total of 232 LMD patients were included. The median age at LMD diagnosis and Karnofsky performance status (KPS) were 54.5 years and 80%, respectively. Most patients presented with LMD localized in the brain (53.8%), underwent RT (66.4%), and received systemic therapy (61.6%). One hundred fifty-four patients received 205 RT courses, with whole-brain RT used most often (120 treatments, 58.5%). With a median follow-up of 4.5 months (range 0.1-72.0 months), 220 deaths were observed. The median overall survival (OS) was 4.7 months (95% confidence interval: 3.9-5.5). RT was not associated with improved OS and showed heterogeneous interactions across clinical contexts. Systemic therapy was associated with improved OS, especially in patients with a poor KPS. DISCUSSION: This study highlights the dismal prognosis of LMD. RT was not associated with improved OS. Our findings, along with the reviewed literature, demonstrate that determining the potential benefit of RT on OS is challenging due to interactions between treatments and their timing, underscoring the need to clarify the optimal use and timing of RT in randomized clinical trials.
引用
- Ehret F, Aitelli A, Niemierko A, et al. The role of radiation therapy in leptomeningeal disease from breast cancer - a multicenter analysis. Clin Transl Radiat Oncol. 2026. PMID: 42699679. doi:10.1016/j.ctro.2026.101259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。